Xenetic Biosciences, Inc. (NasdaqCM: XBIO)
Health Care · Biotechnology · US
$3.85
+7.24% today · +25.5% 1Y
Xenetic Biosciences, Inc. (NasdaqCM: XBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.41M and employs 2 people.
Over the last twelve months the share price has gained 25.5%, trading between 1.90 and 13.93.
Tweenvest scores Xenetic Biosciences, Inc. across four factors: quality 30/100, value 77/100. Its strongest factor is value.
XBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.41M
- Revenue (TTM)
- $3.26M
- P/E
- —
- EPS
- -1.19
- Dividend yield
- —
- Beta (5Y)
- 2.15
- 52-week high
- $13.93
- 52-week low
- $1.90
- Avg volume (3M)
- —
- Shares outstanding
- 2.34M
- Employees
- 2
- Next earnings
- —
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
- ISIN
- US9840156023
- Listed since
- Jun 30, 2016
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.63 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.35 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.75 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.69 | -0.57% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $820.10 | -1.61% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.65 | -7.67% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.